Exception Status Drugs

Certain drugs are only eligible for coverage under the Pharmacare Programs when an individual meets the criteria for coverage developed by the Atlantic and/or Canadian Expert Advisory Committees.

To perform a basic search for specific text in the Criteria for Coverage of Exception Status Drugs (PDF) document:

Press CTRL-F (PC) or Command (⌘)-F (Macintosh). A search box will be displayed in the upper right of the screen. Type the word or phrase you want to search for in the entry field. Use the small left and right arrows in the search box to skip to the previous or next instance of the searched-for word or phrase.

Forms for Exception Status Drug Requests

Copies of the standard request form as well as specialized forms are available below. Forms may be added or changed at any time. To ensure up to date information, please refer to this site.

• Standard Exception Status Drug Request Form (PDF)Request for Coverage Forms
  • Drugs for the Treatment of Diabetes
    • High Cardiovascular Risk- Jardiance® and Synjardy® (PDF)
    • Long-Acting Insulin Analogues (PDF)
    • Non-Insulin Antidiabetic Agents (PDF)
    • Request for Insured Coverage of Sensor-based Glucose Monitoring Products (PDF)
    • Ankylosing Spondylitis (PDF)
    • Psoriatic Arthritis (PDF)
    • Rheumatoid Arthritis (PDF)
    • ADHD (PDF)
    • Benlysta (PDF)
    • Rituximab Biosimilars (PDF)
    • Saphnelo (PDF)
    • Injectable Vitamin B12 (PDF)
    • Parenteral Iron (PDF)
    • Alirocumab (Praluent) and Evolocumab (Repatha) (PDF)
    • Entresto (PDF)
    • Lancora (PDF)
    • Prasugrel (PDF)
    • Ticagrelor (Brilinta) 90mg (PDF)
    • Vyndamax and Vyndaqel (PDF)
    • Cyclosporin (Verkazia) (PDF)
    • Crohn’s Disease Agents (PDF)
    • Proton Pump Inhibitors (PDF)
    • Ulcerative Colitis Agents (PDF)
    • Reblozyl (PDF)
    • Ultomiris aHUS Initial Approval (PDF)
    • Ultomiris aHUS Renewal (PDF)
    • Ultomiris PNH (PDF)
    • Hepatitis C Treatments (PDF)
    • Pre-exposure Prophylaxis for HIV (PDF)
    • Xydalba (PDF)
    • Cinacalcet (Sensipar) (PDF)
    • Sevelamer and Sucroferric Oxyhydroxide (Velphoro) (PDF)
    • Kuvan (PDF)
    • Sebelipase Alfa (Kanuma) (PDF)
    • Agents for Migraine Prevention (PDF)
    • Selective 5HT 1 - Receptor Agonists (PDF)
    • Kesimpta (PDF)
    • Ocrevus (PDF)
    • Siponimod (Mayzent) (PDF)
    • Radicava (PDF)
    • Evenity (PDF)
    • Asthma Inhalers (PDF)
    • Asthma Systemic Agents (PDF)
    • Chronic Obstructive Pulmonary Disease (COPD) Therapy (PDF)
    • Nintedanib (Ofev) (PDF)
    • Adalimumab for Hidradenitis Suppurativa (PDF)
    • Atopic Dermatitis (PDF)
    • Drugs for the Treatment of Psoriasis (PDF)

    More Province of Nova Scotia

    Privacy Terms Crown copyright © 2021, Government of Nova Scotia.